uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective A beta antibody
Eisai Inc, 100 Tice Blvd, Woodcliff Lake, NJ 07677 USA..
Eisai Inc, 100 Tice Blvd, Woodcliff Lake, NJ 07677 USA..
Eisai Inc, 100 Tice Blvd, Woodcliff Lake, NJ 07677 USA..
Eisai Inc, 100 Tice Blvd, Woodcliff Lake, NJ 07677 USA..
Show others and affiliations
2016 (English)In: Alzheimer's Research & Therapy, ISSN 0065-6755, E-ISSN 1758-9193, Vol. 8, 14Article in journal (Refereed) PublishedText
Abstract [en]

Background: Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid beta (A beta) protofibrils.

Methods: Here we describe the first clinical study with BAN2401. Safety and tolerability were investigated in mild to moderate AD. A study design was used with staggered parallel single and multiple ascending doses, from 0.1 mg/kg as a single dose to 10 mg/kg biweekly for four months. The presence of amyloid related imaging abnormalities (ARIA, E for edema, H for hemorrhage) was assessed with magnetic resonance imaging (MRI). Cerebrospinal fluid (CSF) and plasma samples were analyzed to investigate pharmacokinetics (PK) and effects on biomarkers.

Results: The incidence of ARIA-E/H on MRI was comparable to that of placebo. BAN2401 exposure was approximately dose proportional, with a serum terminal elimination half-life of similar to 7 days. Only a slight increase of plasma A beta((1-40)) was observed but there were no measurable effects of BAN2401 on CSF biomarkers. On the basis of these findings Phase 2b efficacy study has been initiated in early AD.

Conclusions: BAN2401 was well-tolerated across all doses. The PK profile has guided us for selecting dose and dose regimens in the ongoing phase 2b study. There was no clear guidance for an effective dose based on biomarkers.

Place, publisher, year, edition, pages
2016. Vol. 8, 14
Keyword [en]
Alzheimer's disease, Amyloid-beta, A beta, Protofibril, Immunotherapy, BAN2401, mAb158, ARIA, Clinical trial
National Category
URN: urn:nbn:se:uu:diva-294671DOI: 10.1186/s13195-016-0181-2ISI: 000373482700001PubMedID: 27048170OAI: oai:DiVA.org:uu-294671DiVA: diva2:932327
Available from: 2016-06-01 Created: 2016-05-26 Last updated: 2016-06-01Bibliographically approved

Open Access in DiVA

fulltext(730 kB)60 downloads
File information
File name FULLTEXT01.pdfFile size 730 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Basun, HansLannfelt, Lars
By organisation
In the same journal
Alzheimer's Research & Therapy

Search outside of DiVA

GoogleGoogle Scholar
Total: 60 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 126 hits
ReferencesLink to record
Permanent link

Direct link